NCT04884555

Brief Summary

In patients undergoing physical therapy after stroke, extracellular thiol-disulfide balance and intracellular oxidized-reduced glutathione balance levels will be monitored. The main objectives of this study are; (1) to determine the differences between thiol-disulfide and GSH-GSSG balances in stroke patients compared to healthy volunteers, (2) to evaluate the relationship of these balances with the severity of stroke, (3) to determine the predictive value of the levels of these balances on clinical prognosis and functional recovery outcomes, and (4) to investigate and to examine the effects of the physical therapy process on these parameters and functional recovery and their relationship with each other.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
77

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2021

Completed
22 days until next milestone

First Posted

Study publicly available on registry

May 13, 2021

Completed
Last Updated

May 13, 2021

Status Verified

May 1, 2021

Enrollment Period

6 months

First QC Date

April 21, 2021

Last Update Submit

May 7, 2021

Conditions

Keywords

strokeThiolDisulphideGlutathione

Outcome Measures

Primary Outcomes (6)

  • NIHSS Scores

    National Institutes Of Health Stroke Scale Scores

    at baseline (pre-treatment)

  • NIHSS Scores

    National Institutes Of Health Stroke Scale Scores

    after 4 weeks of treatment (post-treatment)

  • mRS

    modified Rankin Scales

    at baseline (pre-treatment)

  • mRS

    modified Rankin Scales

    after 4 weeks of treatment (post-treatment)

  • BI

    Barthel Index for Activities of Daily Living

    at baseline (pre-treatment)

  • BI

    Barthel Index for Activities of Daily Living

    after 4 weeks of treatment (post-treatment)

Study Arms (2)

post-stroke patient

patients with subacute stroke who have a stroke for the first time and admitted to the hospital for the first rehabilitation treatments

Other: Standard neurorehabilitationDiagnostic Test: Thiol-Disulphide HomeostasisDiagnostic Test: Oxidized-reduced Glutathione Homeostasis

Control

healthy volunteers who have not got any known disease and any sign in physical examination

Diagnostic Test: Thiol-Disulphide HomeostasisDiagnostic Test: Oxidized-reduced Glutathione Homeostasis

Interventions

Routine post-stroke rehabilitation

post-stroke patient

Monitoring the levels of thiol and disulphide in serum

Controlpost-stroke patient

Monitoring the levels of intracellular oxidized glutathione and reduced glutathione in whole blood samples

Controlpost-stroke patient

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Post-stroke patients group admitted to hospital to take rehablititation and physiotherapy within 1 to 6 months of stroke onset. Healthy adult volunteers (control) group (\> 18 years of age) with no known disease and no findings on physical examination

You may qualify if:

  • diagnosis of a first-ever stroke verified by computed tomography (CT) or magnetic resonance imaging (MRI) reports
  • admitted to the hospital for standard neurorehabilitation within 1 to 6 months of stroke onset
  • healthy individuals (for control group)

You may not qualify if:

  • significant acute medical illness (e.g., autoimmune disease, infection, tumor, heart failure, renal or liver dysfunction)
  • significant acute neurological illness other than stroke (e.g., head trauma, brain abscess, brain tumor, migraine attack, seizure)
  • cannot adapt to work
  • previous history of neurorehabilitation therapy
  • taking the antioxidant supplements

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bolu Abant Izzet Baysal University

Bolu, Turkey (Türkiye)

Location

Related Publications (5)

  • Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989 Jul;20(7):864-70. doi: 10.1161/01.str.20.7.864.

    PMID: 2749846BACKGROUND
  • Kucukdeveci AA, Yavuzer G, Tennant A, Suldur N, Sonel B, Arasil T. Adaptation of the modified Barthel Index for use in physical medicine and rehabilitation in Turkey. Scand J Rehabil Med. 2000 Jun;32(2):87-92.

    PMID: 10853723BACKGROUND
  • Broderick JP, Adeoye O, Elm J. Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. Stroke. 2017 Jul;48(7):2007-2012. doi: 10.1161/STROKEAHA.117.017866. Epub 2017 Jun 16. No abstract available.

    PMID: 28626052BACKGROUND
  • Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem. 2014 Dec;47(18):326-32. doi: 10.1016/j.clinbiochem.2014.09.026. Epub 2014 Oct 7.

    PMID: 25304913BACKGROUND
  • Alisik, M., Neselioglu, S., & Erel, O. (2019). A colorimetric method to measure oxidized, reduced and total glutathione levels in erythrocytes, Journal of Laboratory Medicine, 43(5), 269-277

    BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum and whole blood samples

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Tugba Alisik, MD

    Abant Izzet Baysal University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 21, 2021

First Posted

May 13, 2021

Study Start

July 1, 2020

Primary Completion

January 1, 2021

Study Completion

January 31, 2021

Last Updated

May 13, 2021

Record last verified: 2021-05

Locations